How The Sydney Opera House Became A Symbol Of Sustainability
The Sydney Opera House is more than just an architectural marvel. It's more than the gleaming white sails that grace postcards, Instagram feeds, and travel documentaries. It's more than the iconic backdrop to Australia's New Year's Eve fireworks.
The UNESCO World Heritage site is trying to redefine what it means to be sustainable in the 21st century.
'Sustainability is in our DNA,' says Jess Gooch, the Sydney Opera House's director of strategic engagement and impact.
She's not exaggerating. An innovative seawater cooling system was built into the performing arts center from the start. But can this iconic landmark, once a symbol of modernist ambition, also learn a few new tricks about sustainability in the 21st century? And can visitors become part of its green journey?
Jess Gooch, the Sydney Opera House's director of strategic engagement and impact. Aren Elliott "Embedded" sustainability in Sydney
When Danish architect Jørn Utzon designed the Sydney Opera House in the 1950s, sustainability wasn't a thing. Yet, his vision was remarkably forward-thinking. The building's self-cleaning tiles and seawater cooling system were groundbreaking.
'Utzon was way ahead of his time,' Gooch explains. 'He embedded sustainability into the design from the very beginning.'
But the Opera House's sustainability journey was just getting started. Fast-forward to 2019, when the organization adopted the United Nations Sustainable Development Goals, committing to achieve them by 2030.
This wasn't just a PR move, says Gooch. It was a call to action.
'We realized we had to bring all our efforts under one umbrella,' Gooch says. 'Environmental sustainability, equity, inclusion, accessibility — they're all interconnected.'
To streamline its efforts, the Opera House restructured its teams, creating an 'impact function' that combines these previously siloed areas.
'We wanted to think about sustainability holistically,' Gooch adds. 'It's not just about reducing emissions; it's about creating a stage for diverse voices, preserving heritage, and inspiring others to take action.' How the Sydney Opera House became more sustainable
The Sydney Opera House's sustainability efforts are as diverse as its programming. Here's a snapshot of what's happening behind the scenes: Improved building operations. The Opera House has reduced its emissions by 26 percent and now runs on 100 percent renewable energy. It's also achieved a 6-star Green Star Performance rating from the Green Building Council of Australia, which means it officially uses 10 to 40 percent less energy than a comparable facility.
The Opera House has reduced its emissions by 26 percent and now runs on 100 percent renewable energy. It's also achieved a 6-star Green Star Performance rating from the Green Building Council of Australia, which means it officially uses 10 to 40 percent less energy than a comparable facility. Better waste management. Over 90 percent of event waste is diverted from landfills, thanks to robust recycling and composting programs.
Over 90 percent of event waste is diverted from landfills, thanks to robust recycling and composting programs. Biodiversity. The Opera House has installed an artificial reef to promote marine biodiversity. 'We've even spotted a rare white seahorse there,' Gooch notes.
There are also improvements outside the traditional sustainability discipline. For example, the Opera House wants to make more of a social impact, and it is committed to showcasing diverse voices, from First Nations artists to contemporary performers. Its collaboration with the Sydney Festival on projects like Thaw — a melting iceberg installation highlighting climate change — shows how art can drive meaningful conversations about sustainability.
The facility is also trying to be more accessible. It has invested heavily in new pathways, elevators and escalators.
'This building wasn't designed with accessibility in mind,' Gooch admits. 'But we're changing that.' Can visitors see the Sydney Opera House's sustainability when they visit?
You don't have to be a sustainability expert to notice the Opera House's green initiatives. If you visit Sydney, you can see the building's sustainability mission on display in big and small ways.
For example, during events like Vivid LIVE, the Opera House's annual contemporary music program, the facility offers guests reusable cups to reduce single-use plastic.
Once a month, the facility also offers a sustainability tour, where guests can see the Opera House's green initiatives behind the scenes, including its original cooling system. It also runs a digital sustainability tour exclusively for schools to educate kids about its sustainability efforts and to foster environmental awareness.
You can also see art, which is a key part of the Opera House's cultural sustainability program. The Balu Gilly projection on the building's sails is a nightly First Nations artwork that connects visitors to the land's cultural heritage. What's the future? Electrification — and adaptation
The Opera House isn't resting on its laurels. Its next big focus is decarbonization.
'We're looking at electrifying everything — our kitchens, our venues, even our shuttles,' Gooch explains. 'We want to remove any reliance on fossil fuels.'
But the challenges are real, too. Rising sea levels pose a threat to the Opera House's harborside location. Indeed, when the building was constructed in the late 1960s and early 70s, no one was concerned about rising sea levels — or that the building might someday be under water.
'We're closely monitoring sea levels and working on a climate adaptation plan,' Gooch says. 'We're also thinking about how to future-proof the building against extreme heat and wind.'
The Sydney Opera House is an example of what's possible when art, culture, and sustainability intersect.
'We want people to see, touch, and feel what we're doing,' Gooch says. 'We want to make sustainability real for everyone.'
As the Opera House continues its journey toward sustainability, its impact will extend far beyond Sydney Harbour. It's an example of what's possible and perhaps proves that even the most iconic landmarks can adapt and innovate.
So, the next time you visit Sydney, take a moment to appreciate not just the beauty of the Opera House's sails, but the futuristic vision behind them.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Major banks slash interest rates despite RBA cash rate hold: 'Not a coincidence'
Numerous banks, including NAB and ANZ, have cut interest rates on term deposit and fixed home loans despite the Reserve Bank of Australia (RBA) holding the cash rate steady. The central bank defied expectations by keeping the cash rate at 3.85 per cent last week, but that doesn't mean lenders aren't moving. NAB cut its term deposit rates today, with decreases of between 5 to 20 basis points across multiple terms. Its 7-month term has been cut by 20 basis points, bringing its leading rate down to 3.80 per cent. Mozo personal finance expert Rachel Wastell told Yahoo Finance the bank was one of 17 banks who had made term deposit cuts following the RBA's decision. RELATED Major banks reveal updated RBA interest rate cut predictions after 'surprise' hold ATO tax return warning for 2 million Aussies over dangerous act Bendigo Bank customers fight against branch closure amid cashless revolution 'When 17 banks, both big and small, slash term deposits within a week it's not a coincidence, it's a signal,' she said. 'Even after the RBA held, the market kept on cutting these forward-looking products, which shows that lenders are most likely preparing for more rate cuts and that the easing cycle is well and truly underway.' Fellow Big Four bank ANZ trimmed its 8-month Advance notice term deposit by 10 basis points on Wednesday, bringing its highest rate down to 3.80 per cent. Other banks that have moved rates downwards include Bank Australia, Judo Bank, and People's Choice. Fixed home loan rates are also falling, with Mozo seeing four lenders cut rates following the RBA decision. On Wednesday, QBANK cut its fixed rates by 20 to 30 basis points, with SWS Bank, Coastline Bank and The Capricornian following suit. Wastell said it was a rate shift and 'both savers and borrowers should take the hint'. 'If banks thought rates were staying put, we wouldn't be seeing term deposits and fixed-rate home loans falling,' she said. 'Fixed rates and term deposits are forward-looking products, so banks adjust them based on where they expect the cash rate (and wholesale funding costs) will go. 'The fact that both big and small lenders are trimming fixed rates across home loans and deposits, even after the RBA paused last week, suggests they're confident further cash rate cuts are coming and want to get ahead of the curve.'The major banks all expect the RBA will cut interest rates at the August meeting. They are then split on how many more interest rate cuts are coming. Here are their current forecasts: CBA: Two more cuts in August and November to bring cash rate to 3.35 per cent Westpac: Four more cuts in August, November, February and May to bring cash rate to 2.85 per cent NAB: Three more cuts in August, November and February to bring cash rate to 3.10 per cent ANZ: Two more cuts in August and November to bring cash rate to 3.35 per cent On a $600,000 mortgage, Canstar calculated two further cuts could see minimum repayments drop by almost $180. If there are four cuts, minimum repayments could drop by up to $350, depending on the timing of the cuts. While further RBA interest rate cuts will be good news for mortgage holders, it has sparked a warning for savers. Wastell told Yahoo Finance the 'window is closing' for savers holding out for a better deal. 'Those peak term deposit rates are already behind us and banks are clearly repositioning for the next phase of cuts. This round of cuts tells us they're betting on more to come, and that even these lower rates won't be around for much longer,' she said. 'If you're thinking about locking in a deposit, now would be the time to move. The banks aren't waiting for the RBA, and the leading rates are only getting lower.'Sign in to access your portfolio
Entrepreneur
an hour ago
- Entrepreneur
Quild Reimagines the Art of Modern Quilting in Dubai
The brand operates with sustainability at its core and follows a conscious approach to fabric consumption to minimize the impact on the environment. You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. Known for their artistic and distinctive handcrafted quilts and diverse quilting products, Dubai-based quilt brand Quild blends classic quilting techniques with modern, contemporary design, offering a selection of unique and sustainable pieces for fashion as well as home décor. The brand is the brainchild of Farida Talaat, a talented artist and designer who grew up in Dubai and studied in Canada. She dabbled in arts and crafts, sewing, and fashion design before specializing in designing and sewing quilts and quilted products. Quild reimagines the old-world craft of traditional quilting. Made of high-quality natural fabrics such as cotton, linen, or a blend of both, their products are as aesthetic as they are functional. Quild's collections and product lines include bed-size quilts, children's quilts, quilted blankets, throws, jackets, hand bags and beach bags, makeup pouches, and other soft furnishings and accessories that can be used around the home. Each piece is meticulously designed to ensure beauty, comfort and functionality all around. The quilts' artistic appeal doesn't end there, with all quilts being made sustainably using eco-friendly fabric and material. The brand operates with sustainability at its core and follows a conscious approach to fabric consumption to minimize the impact on the environment. We speak to Farida Talaat about her quilting journey. Tell us about the early beginnings of Quild. What inspired you to start a quilting business in the UAE? My passion for quilts began in Dubai in 2017, when I designed and produced my first quilt by myself without any prior training or experience. Then, after moving to Canada, I learned the basics of the craft by connecting with quilting groups and collaborating with quilting professionals in Canada and the United States. I immediately loved quilts because they evoke an authentic old-world feel and a sense of nostalgia. Describe your creative process, and what steps you take to ensure no two items are alike? The process of designing any quilt begins with thoughtful planning as to the layout of the colors and patterns of the overall quilt. I then decide on the concept and artistic vision for the piece Then I begin by selecting and arranging fabrics based on color, print and texture. After determining the overall shape, I cut the fabric and expertly hand-sew the quilt using a quilting technique, which involves sewing and passing threads across the surface and bottom of the fabric to secure the layers together, creating a single cohesive quilt. Once the sewing is complete, the final touches are applied like adding a label and ensuring quality. The process of sewing quilts is a laborious, but it's a fine process that requires artistic flair and dextrous skill. It is also very time-consuming. Each quilt is considered a valuable and unique piece in and of itself because of the amount of work that goes into it. Throughout my work, I brainstorm and take my time in designing and refining my creations. I also focus a lot on hand sewing which ensures that no two pieces are ever alike. How do you obtain the raw materials you use in manufacturing your products? All Quild products are made from premium fabrics and fabric blends. I work on purchasing special fabrics and sewing supplies from retail and wholesale traders in the UAE. I also contract wholesale fabric suppliers to import the raw materials I need from around the world. On my trips to Canada and the USA, I visit haberdashery and notions shops to buy unique accoutrements. Can you share an example of a custom design request from a client and how you brought their vision to life? One time we received a request from a mother who commissioned a quilt to be made from her daughter's clothes when she was a baby. We cut the small garments to highlight the best parts and then sewed them together in a patchwork style. She was really happy with it as it was a meaningful keepsake for her and her daughter. There are other instances where we receive requests to create 3D quilts or orders that include embroidery of specific words in colored thread, as well as ones with striking vibrant designs. A client would submit a custom request via an online order. The first step in the design process is conceptualisation where I draw on experience and inspiration to envisage the look of the quilt. I start thinking about the design, taking into consideration the feel of the fabric, texture, material, size, thickness, weight, and final shape. We then begin to create the quilt by cutting the fabric, stitching, quilting and lastly binding. Sometimes we embroider names or birth dates on each quilt, depending on the client's request, to create something truly bespoke. Then comes packaging. We carefully wrap the order and prepare it for shipping and delivering it directly to the customer. I also make sure to follow up with customers after delivery to ensure their satisfaction and answer their queries. Source: Farida Talaat Can you describe your eco-friendly production practices? In recent years, we started working a lot on sustainable quilts with 'green' materials and waste-efficient techniques. We select the optimal fabrics for each type of quilt to ensure their efficiency and prolong the life cycle of each product. Most of our quilts are made of sustainably-sourced material; some are made from lightweight smart fabrics that serve dual functions making the quilts suitable for both winter and summer. We also follow intelligent and thoughtful fabric cutting practices to minimize fabric waste. Additionally, we use the surplus of fabric to create quilted products and accessories, creating new one-of-a-kind pieces full of spontaneity and individuality. Who is your target audience/groups that purchase your products? We attract several slices of the market and community. Among our most important clients are parents looking to buy baby blankets for their little ones or as gifts to other families with newborns. In addition to art enthusiasts seeking unconventional artistic objects with modern designs. We are often approached by interior designers, home stylists, and real estate staging and marketing firms wanting to stage their properties with unique and eye-catching pieces and quilts as alternatives to paintings. Our quilts can be used as bed spreads, covers for sofas and chairs, but also tablecloths and wall hangings. How did you finance the project and how are you looking for funding? In the early stages, the project was financed from my own funds as well as from angel investors. Initially I set a specific budget for it and gradually it started generating profit. With more revenue coming in we then followed a revenue-based financing model and began to use a percentage of revenues to reinvest into the business and repay investors. Lately, we approached other investors for more substantial funding to allow for growth and scaling. How do you achieve returns and profits from your work, and how do you market the product? To ensure the project's profitability and achieve optimum returns, we make sure to keep expenses within reasonable limits, in addition to constantly studying the pricing policy and negotiating with wholesale fabric suppliers. Our Marketing is carried out through several channels including displaying our products directly at brick-and-mortar stores, as well as online. We complement this with direct public relations, and advertising through social media and partaking in pop-up markets, exhibitions and events. What are your plans for the future? Are there any new products or initiatives on the horizon? We are currently working on launching a new fall collection inspired by the glorious colours of a Canadian fall season. In addition to speaking to a number of e-commerce retailers for potential partnerships over the coming months. As one of the first quilt art studios in the UAE, we plan on organizing a quilt exhibition in the UAE soon to serve as a collaborative platform for quilting professionals, fabric wholesalers and quilt enthusiasts. We are also preparing to design and create special quilts to celebrate the UAE's 54th National Day in December, 2025. All this while carrying on our operations to fulfill customer orders without interruption. What advice would you offer ambitious women entrepreneurs, especially those looking to start a business in a niche market like sewing and quilting? A key piece of advice is to use the skills you acquired during your corporate career to support your business. Also focus on one specialty area and master it, rather than succumb to the pressure of diversifying and offering multiple types of products without a focus on each. Believe in your product and do work you care about. I truly believe that if you attach a personal meaning to your project, its chances of success increase ten-fold!
Yahoo
2 hours ago
- Yahoo
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood cancer First patient remains cancer free at 15 months and ongoing with additional patients having durable responses at 2, 5, and 11 months+ and durability data continuing to mature Patients in the trial have previously failed at least 3 lines of therapy with many patients failing 4-6 lines of therapy, including autologous CAR-T, reinforcing the potential of azer-cel in this high-unmet-need population Based on these positive results, Imugene expects to meet with the US FDA in Q4 2025 regarding a pivotal / registrational study for azer-cel Trial now open to enrol into CAR T naïve niche indications in other lymphomas Additional update expected in coming months SYDNEY, July 14, 2025 /PRNewswire/ -- Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In February 2025, Imugene announced that a total of four out of seven patients had achieved a Complete Response (CR), defined as the disappearance of all signs of cancer in response to treatment. Since then, two additional patients have also achieved a Complete Response, and three patients have achieved Partial Response (cancer reduction by at least 50%) bringing the best overall response rate to 75% and the CR rate to 55%. The duration of response continues to mature. These patients are being treated with azer-cel and interleukin 2 (IL -2). Evaluable patients Treatment N Overall Response Rate (ORR) Complete Response (CR) At Day 60 Best Durability (Time of response) DLBCL Lymphodepletion (LD)1 +azer-cel +Interleukin-2 (IL-2) 12 9/12 (75%) 6/11 (55%) >450 days on going For approved, autologous CD19 CART products, the average time to best response is 2-3 months with some patients taking up to 6 months to achieve their best response. Azer-cel is being developed as a potential allogeneic, off-the-shelf, CAR T-cell therapy, addressing key limitations of approved autologous CAR T drugs, including geographical access to treatment centres, manufacturing complexity and time to receive treatment (on-demand). Based on the updated response rate and maturing durability data, as well as having been awarded FDA Fast Track Designation for DLBCL in March 2025, Imugene will request a Type B (End of Phase 1) Meeting in Q4 2025, with the US FDA to present the data and to discuss designs for a pivotal / registrational trial for azer-cel. Leslie Chong, Managing Director and CEO of Imugene, said: "We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for DLBCL patients who have failed several previous lines of therapy. The data also significantly improves our position from both a regulatory and commercial standpoint, and we look forward to expanding on these discussions with the FDA. Additionally, given the positive results, we are opening the trial to other niche blood cancer indications, such as PCNSL and other subtypes of B Cell Lymphoma, for CAR T naïve patients. This is a high unmet need with potential to expedite and expand the scope of azer-cel." Dr John Byon, Chief Medical Officer of Imugene, said: "DLBCL remains one of the most aggressive forms of lymphoma, and despite the existing therapies, there are a large number of patients that still face relapse or resistance. We are seeing significant potential from azer-cel to date in its ability to provide a critical step forward for these patients who have relapsed on multiple therapies, offering deep and durable responses with a one-time treatment. We remain deeply committed to transforming the standard of care in difficult-to-treat blood cancers, where significant unmet medical need still exists." The FDA Fast Track Designation for DLBCL received for azer-cel is designed to facilitate the development and expedite the review of drugs that address serious or life-threatening conditions and meet an unmet medical need. Benefits of the designation include more frequent meetings with the FDA to discuss development plans, the option for rolling review of regulatory submissions, and potential eligibility for Accelerated Approval and Priority Review upon meeting relevant criteria. Imugene continues to actively enrol patients into the Phase 1b azer-cel trial at ten US sites with up to six sites in Australia planned, after the first Australian patient was dosed in January 2025 at Royal Prince Alfred Hospital in Sydney, resulting in a Complete Response. About the Phase 1b azer-cel trial The azer-cel allogeneic CAR T trial is an ongoing, open-label, multi-centre Phase 1b clinical trial in the U.S. and Australia, for CAR T relapsed patients with DLBCL. The study has recently expanded to include and treat CAR T naïve patients diagnosed with a broad range of Non-Hodgkins lymphomas including primary central nervous system lymphoma (PCNSL), chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM) and follicular lymphoma (FL). Treatment with azer-cel, lymphodepletion (LD) and IL-2 is showing promising results with evidence of meaningful clinical activity, and durability of response. Additionally, the safety profile is manageable and generally well tolerated. About diffuse large B cell lymphoma (DLBCL) DLBCL is an aggressive and fast-growing type of non-Hodgkin's lymphoma (NHL), a type of blood cancer. DLBCL is the most common type of NHL, with approximately 160,000[1] global cases per year and approximately 30,000 new cases per year in the U.S. Relapsed/refractory DLBCL has a high unmet medical need; ~60% of patients treated with approved autologous CD19 CAR T relapse. [1]Science Direct Volume 60, Issue 5, November 2023 About primary central nervous system lymphoma (PCNSL) PCNSL is a rare and aggressive form of non-Hodgkin lymphoma (NHL), a type of blood cancer that originates in the brain, spinal cord, leptomeninges, or eyes, usually without evidence of systemic disease. In the U.S., there are approximately 1,500 to 1,800 new cases per year with limited approved treatment options and is a high unmet need. Currently, there are no CAR T-cell products approved for the treatment of PCNSL providing a unique opportunity for azer-cel to treat CART naïve patients. About other types of B Cell Lymphoma Other subtypes of non-Hodgkin lymphoma (NHL) include chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the most common slow growing leukemia that can become resistant to therapy; marginal zone lymphoma (MZL), a slow-growing B-cell lymphoma that arises in lymphoid tissues associated with mucosal sites like the stomach and lung; Waldenström macroglobulinemia (WM), a rare slow-growing lymphoma characterized by excess IgM production, which can cause multiple complications ; and follicular lymphoma (FL), a common slow-growing NHL that can become more aggressive. While several targeted therapies and monoclonal antibodies are available for these types of B Cell Lymphoma, relapsed or refractory disease remains an ongoing challenge, highlighting the ongoing need for continued innovation and new and better treatments. About Interleukin 2 (IL-2) IL-2 is a cytokine (a protein that affects what happens between cells in the immune system) that helps T-cells (which are part of the immune system that help fight cancer) grow and survive. IL-2 has been shown to help T cells live longer and to enhance the cancer killing functions of CAR T cells, making them more effective at targeting and killing cancer cells. For more information please contact: Leslie ChongManaging Director and Chief Executive Officerinfo@ General Investor Enquiriesshareholderenquiries@ Media EnquiriesMatt Wrightmatt@ Connect with us on LinkedIn @Imugene LimitedFollow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited About Imugene (ASX:IMU) Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours and B-cell vaccine candidates. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market. Release authorised by the Managing Director and Chief Executive Officer Imugene Limited. View original content to download multimedia: SOURCE Imugene Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
